Assertio Completes $23.50 Per Share Acquisition by Zydus Lifesciences — Assertio Holdings, Inc.

Event summary

Assertio Holdings completed its merger with Zydus Lifesciences on June 16, 2026, delisting from Nasdaq.
Assertio shareholders received $23.50 per share in cash.
Holders of Assertio's 6.50% Convertible Senior Notes due 2027 have until July 16, 2026, to exercise repurchase or conversion rights.
Conversion of notes will yield approximately $382.58 per $1,000 principal amount.

The big picture

This acquisition marks Zydus Lifesciences' entry into the U.S. pharmaceutical market through a specialized oncology player. The deal reflects a broader trend of international pharmaceutical companies acquiring U.S. assets to gain market access and diversify product portfolios. The $23.50 per share price suggests Zydus sees value in Assertio's commercial infrastructure and differentiated product offerings.

What we're watching

Integration Challenges: How Zydus will integrate Assertio's oncology-focused portfolio into its existing operations.
Debt Repurchase Impact: Whether noteholders will exercise repurchase rights, affecting Assertio's cash position.
Market Positioning: The pace at which Zydus can leverage Assertio's commercial capabilities to expand market reach.